Differences_NNS
in_IN
phosphorylation_NN
of_IN
the_DT
IL-2R_NN
associated_VBD
JAK\/STAT_JJ
proteins_NNS
between_IN
HTLV-I_NN
-LRB-_-LRB-
+_NN
-RRB-_-RRB-
,_,
IL-2-independent_JJ
and_CC
IL-2-dependent_JJ
cell_NN
lines_NNS
and_CC
uncultured_JJ
leukemic_JJ
cells_NNS
from_IN
patients_NNS
with_IN
adult_JJ
T-cell_NN
lymphoma\/leukemia_NN
._.

To_TO
determine_VB
activation_NN
status_NN
of_IN
the_DT
IL-2R-associated_JJ
-LRB-_-LRB-
Jak\/STAT_NN
-RRB-_-RRB-
pathway_NN
in_IN
the_DT
HTLV-I_NN
infected_JJ
cells_NNS
,_,
we_PRP
examined_VBD
tyrosine_NN
phosphorylation_NN
of_IN
Jak3_NN
,_,
STAT3_NN
,_,
and_CC
STAT5_NN
in_IN
several_JJ
HTLV-I_NN
-LRB-_-LRB-
+_JJ
-RRB-_-RRB-
T-cell_NN
lines_NNS
and_CC
in_IN
uncultured_JJ
leukemic_JJ
T_NN
cells_NNS
isolated_VBN
from_IN
patients_NNS
with_IN
adult_JJ
T-cell_NN
lymphoma\/leukemia_NN
-LRB-_-LRB-
ATLL_NN
-RRB-_-RRB-
._.

Constitutive_JJ
basal_JJ
phosphorylation_NN
of_IN
Jak3_NN
and_CC
,_,
usually_RB
,_,
STAT3_NN
and_CC
STAT5_NN
was_VBD
detected_VBN
in_IN
all_DT
four_CD
IL-2-independent_JJ
cell_NN
lines_NNS
tested_VBN
,_,
but_CC
in_IN
none_NN
of_IN
the_DT
three_CD
IL-2-dependent_JJ
cell_NN
lines_NNS
._.

Similarly_RB
,_,
there_EX
was_VBD
no_DT
detectable_JJ
basal_JJ
phosphorylation_NN
of_IN
Jak3_NN
and_CC
STAT5_NN
in_IN
the_DT
leukemic_JJ
cells_NNS
from_IN
ATLL_NN
patients_NNS
-LRB-_-LRB-
0\/8_CD
and_CC
0\/3_CD
,_,
respectively_RB
-RRB-_-RRB-
._.

However_RB
,_,
stimulation_NN
with_IN
IL-2_NN
resulted_VBD
in_IN
Jak3_NN
and_CC
STAT5_NN
phosphorylation_NN
in_IN
both_CC
leukemic_JJ
ATLL_NN
cells_NNS
and_CC
IL-2-dependent_JJ
lines_NNS
._.

Furthermore_RB
,_,
expression_NN
of_IN
SHP-1_NN
phosphatase_NN
which_WDT
is_VBZ
a_DT
negative_JJ
regulator_NN
of_IN
cytokine_NN
receptor_NN
signaling_NN
,_,
was_VBD
lost_VBN
in_IN
most_JJS
IL-2_NN
independent_JJ
cell_NN
lines_NNS
-LRB-_-LRB-
3\/4_CD
-RRB-_-RRB-
but_CC
not_RB
in_IN
the_DT
leukemic_JJ
ATLL_NN
cells_NNS
-LRB-_-LRB-
0\/3_CD
-RRB-_-RRB-
._.

Finally_RB
,_,
the_DT
HTLV-I_NN
-LRB-_-LRB-
+_NN
-RRB-_-RRB-
T-cell_NN
lines_NNS
-LRB-_-LRB-
313_CD
-RRB-_-RRB-
but_CC
not_RB
the_DT
control_NN
,_,
HTLV-I_NN
-LRB-_-LRB-
-_NN
-RRB-_-RRB-
T-cell_NN
lines_NNS
were_VBD
resistant_JJ
to_TO
rapamycin_NN
and_CC
its_PRP$
novel_JJ
analog_NN
RAD_NN
._.

We_PRP
conclude_VBP
that_IN
-LRB-_-LRB-
1_LS
-RRB-_-RRB-
HTLV-I_NN
infection_NN
per_FW
se_FW
does_VBZ
not_RB
result_VB
in_IN
a_DT
constitutive_JJ
phosphorylation_NN
of_IN
the_DT
Jak3_NN
,_,
STAT3_NN
,_,
and_CC
STAT5_NN
proteins_NNS
;_:
-LRB-_-LRB-
2_LS
-RRB-_-RRB-
malignant_JJ
transformation_NN
in_IN
at_IN
least_JJS
some_DT
cases_NNS
of_IN
ATLL_NN
does_VBZ
not_RB
require_VB
the_DT
constitutive_JJ
,_,
but_CC
may_MD
require_VB
IL-2-induced_JJ
,_,
activation_NN
of_IN
the_DT
IL-2R_NN
Jak\/STAT_NN
pathway_NN
;_:
and_CC
-LRB-_-LRB-
3_LS
-RRB-_-RRB-
there_EX
are_VBP
major_JJ
differences_NNS
in_IN
T-cell_NN
immortalization_NN
mechanism_NN
-LRB-_-LRB-
s_NNS
-RRB-_-RRB-
which_WDT
appear_VBP
to_TO
involve_VB
SHP-1_NN
and_CC
target_NN
molecules_NNS
for_IN
rapamycin_NN
and_CC
RAD_NN
._.

